{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:05:33Z","timestamp":1773795933575,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,17]]},"DOI":"10.7759\/cureus.105398","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T21:05:09Z","timestamp":1773781509000},"source":"Crossref","is-referenced-by-count":0,"title":["How Does Lymphocyte Depletion Affect Rectal Cancer Radiotherapy Outcomes?"],"prefix":"10.7759","author":[{"given":"Zineb","family":"Dahbi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reyzane","family":"El Mjabber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rim","family":"Alami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmine","family":"Harrar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadila","family":"Guessous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer RR","year":"2021","unstructured":"Bahadoer RR, Dijkstra EA, van Etten B, et al.. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021, 22:29-42. 10.1016\/S1470-2045(20)30555-6","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy T","year":"2021","unstructured":"Conroy T, Bosset JF, Etienne PL, et al.. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021, 22:702-15. 10.1016\/S1470-2045(21)00079-6","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01667","article-title":"Multicenter, randomized, Phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR)","volume":"40","author":"Jin J","year":"2022","unstructured":"Jin J, Tang Y, Hu C, et al.. Multicenter, randomized, Phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol. 2022, 40:1681-92. 10.1200\/JCO.21.01667","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz186","article-title":"Long-course preoperative chemoradiation versus 5 \u00d7 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study","volume":"30","author":"Cise\u0142 B","year":"2019","unstructured":"Cise\u0142 B, Pietrzak L, Michalski W, et al.. Long-course preoperative chemoradiation versus 5 \u00d7 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol. 2019, 30:1298-303. 10.1093\/annonc\/mdz186","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: functions of cells recruited to the tumor microenvironment","volume":"21","author":"Hanahan D","year":"2012","unstructured":"Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012, 21:309-22. 10.1016\/j.ccr.2012.02.022","journal-title":"Cancer Cell"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan D","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011, 144:646-74. 10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail DF","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013, 19:1423-37. 10.1038\/nm.3394","journal-title":"Nat Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246206","article-title":"The colorectal cancer tumor microenvironment and its impact on liver and lung metastasis","volume":"13","author":"Chandra R","year":"2021","unstructured":"Chandra R, Karalis JD, Liu C, et al.. The colorectal cancer tumor microenvironment and its impact on liver and lung metastasis. Cancers (Basel). 2021, 13:6206. 10.3390\/cancers13246206","journal-title":"Cancers (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071586","article-title":"The role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer","volume":"18","author":"Senthebane DA","year":"2017","unstructured":"Senthebane DA, Rowe A, Thomford NE, et al.. The role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer. Int J Mol Sci. 2017, 18:1586. 10.3390\/ijms18071586","journal-title":"Int J Mol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.01.004","article-title":"Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer","volume":"40","author":"Nicolas AM","year":"2022","unstructured":"Nicolas AM, Pesic M, Engel E, et al.. Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. Cancer Cell. 2022, 40:168-84. 10.1016\/j.ccell.2022.01.004","journal-title":"Cancer Cell"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3958","article-title":"The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence","volume":"15","author":"Barker HE","year":"2015","unstructured":"Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015, 15:409-25. 10.1038\/nrc3958","journal-title":"Nat Rev Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3109\/07357907.2012.762780","article-title":"The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells","volume":"31","author":"Yovino S","year":"2013","unstructured":"Yovino S, Kleinberg L, Grossman SA, Narayanan M, Ford E. The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Invest. 2013, 31:140-4. 10.3109\/07357907.2012.762780","journal-title":"Cancer Invest"},{"key":"ref13","article-title":"CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma","volume":"63","author":"Cho Y","year":"2003","unstructured":"Cho Y, Miyamoto M, Kato K, et al.. CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res. 2003, 63:1555-9.","journal-title":"Cancer Res"},{"key":"ref14","article-title":"Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas","volume":"61","author":"Schumacher K","year":"2001","unstructured":"Schumacher K, Haensch W, R\u00f6efzaad C, et al.. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. 2001, 61:3932-6.","journal-title":"Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0774","article-title":"Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide","volume":"17","author":"Grossman SA","year":"2011","unstructured":"Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, Piantadosi S. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011, 17:5473-80. 10.1158\/1078-0432.CCR-11-0774","journal-title":"Clin Cancer Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/hed.24158","article-title":"Minimum absolute lymphocyte count during radiotherapy as a new prognostic factor for nasopharyngeal cancer","volume":"38","author":"Cho O","year":"2016","unstructured":"Cho O, Oh YT, Chun M, Noh OK, Hoe JS, Kim H. Minimum absolute lymphocyte count during radiotherapy as a new prognostic factor for nasopharyngeal cancer. Head Neck. 2016, 38:E1061-7. 10.1002\/hed.24158","journal-title":"Head Neck"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.04.025","article-title":"Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes","volume":"89","author":"Tang C","year":"2014","unstructured":"Tang C, Liao Z, Gomez D, et al.. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys. 2014, 89:1084-91. 10.1016\/j.ijrobp.2014.04.025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-5-47","article-title":"Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer","volume":"5","author":"Kitayama J","year":"2010","unstructured":"Kitayama J, Yasuda K, Kawai K, Sunami E, Nagawa H. Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer. Radiat Oncol. 2010, 5:47. 10.1186\/1748-717X-5-47","journal-title":"Radiat Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e3182940ff9","article-title":"The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma","volume":"38","author":"Wild AT","year":"2015","unstructured":"Wild AT, Ye X, Ellsworth SG, et al.. The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma. Am J Clin Oncol. 2015, 38:259-65. 10.1097\/COC.0b013e3182940ff9","journal-title":"Am J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0151","article-title":"Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors","volume":"13","author":"Grossman SA","year":"2015","unstructured":"Grossman SA, Ellsworth S, Campian J, et al.. Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors. J Natl Compr Canc Netw. 2015, 13:1225-31. 10.6004\/jnccn.2015.0151","journal-title":"J Natl Compr Canc Netw"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2019.12.003","article-title":"Lymphocyte-sparing radiotherapy: The rationale for protecting lymphocyte-rich organs when combining radiotherapy with immunotherapy","volume":"30","author":"Lambin P","year":"2020","unstructured":"Lambin P, Lieverse RI, Eckert F, et al.. Lymphocyte-sparing radiotherapy: The rationale for protecting lymphocyte-rich organs when combining radiotherapy with immunotherapy. Semin Radiat Oncol. 2020, 30:187-93. 10.1016\/j.semradonc.2019.12.003","journal-title":"Semin Radiat Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2019.01.005","article-title":"Radiation-related lymphopenia after pelvic nodal irradiation for prostate cancer","volume":"4","author":"Schad MD","year":"2019","unstructured":"Schad MD, Dutta SW, Muller DM, Wijesooriya K, Showalter TN. Radiation-related lymphopenia after pelvic nodal irradiation for prostate cancer. Adv Radiat Oncol. 2019, 4:323-30. 10.1016\/j.adro.2019.01.005","journal-title":"Adv Radiat Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-023-02205-8","article-title":"The relationship between the radiation dose of pelvic-bone marrow and lymphocytic toxicity in concurrent chemoradiotherapy for cervical cancer","volume":"18","author":"Zhang BZ","year":"2023","unstructured":"Zhang BZ, Li Y, Xu LM, et al.. The relationship between the radiation dose of pelvic-bone marrow and lymphocytic toxicity in concurrent chemoradiotherapy for cervical cancer. Radiat Oncol. 2023, 18:12. 10.1186\/s13014-023-02205-8","journal-title":"Radiat Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.phro.2022.07.006","article-title":"Lymphocyte-sparing pelvic radiotherapy for prostate cancer: An in-silico study","volume":"23","author":"Bar\u00e9 M","year":"2022","unstructured":"Bar\u00e9 M, Poeta S, Fernandes P, et al.. Lymphocyte-sparing pelvic radiotherapy for prostate cancer: An in-silico study. Phys Imaging Radiat Oncol. 2022, 23:127-33. 10.1016\/j.phro.2022.07.006","journal-title":"Phys Imaging Radiat Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101842","article-title":"Hematologic toxicity and bone marrow-sparing strategies in chemoradiation for locally advanced cervical cancer: a systematic review","volume":"16","author":"Konnerth D","year":"2024","unstructured":"Konnerth D, Gaasch A, Zinn A, et al.. Hematologic toxicity and bone marrow-sparing strategies in chemoradiation for locally advanced cervical cancer: a systematic review. Cancers (Basel). 2024, 16:1842. 10.3390\/cancers16101842","journal-title":"Cancers (Basel)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1201500","article-title":"A review on lymphocyte radiosensitivity and its impact on radiotherapy","volume":"13","author":"Paganetti H","year":"2023","unstructured":"Paganetti H. A review on lymphocyte radiosensitivity and its impact on radiotherapy. Front Oncol. 2023, 13:1201500. 10.3389\/fonc.2023.1201500","journal-title":"Front Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2021.09.009","article-title":"Correlations between bone marrow radiation dose and hematologic toxicity in locally advanced cervical cancer patients receiving chemoradiation with cisplatin: a systematic review","volume":"164","author":"Corbeau A","year":"2021","unstructured":"Corbeau A, Kuipers SC, de Boer SM, Horeweg N, Hoogeman MS, Godart J, Nout RA. Correlations between bone marrow radiation dose and hematologic toxicity in locally advanced cervical cancer patients receiving chemoradiation with cisplatin: a systematic review. Radiother Oncol. 2021, 164:128-37. 10.1016\/j.radonc.2021.09.009","journal-title":"Radiother Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-020-01659-z","article-title":"Dose-volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer","volume":"196","author":"Kuncman \u0141","year":"2020","unstructured":"Kuncman \u0141, Stawiski K, Mas\u0142owski M, Kucharz J, Fijuth J. Dose-volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer. Strahlenther Onkol. 2020, 196:998-1005. 10.1007\/s00066-020-01659-z","journal-title":"Strahlenther Onkol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s003840050072","article-title":"Pathological features of rectal cancer after preoperative radiochemotherapy","volume":"12","author":"Dworak O","year":"1997","unstructured":"Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997, 12:19-23. 10.1007\/s003840050072","journal-title":"Int J Colorectal Dis"},{"key":"ref30","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. (2017). Accessed. 2026: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf."},{"key":"ref31","unstructured":"TNM Classification of Malignant Tumours. (2024). Accessed. 2026: https:\/\/www.uicc.org\/resources\/tnm-classification-malignant-tumours-8th-edition."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.08.070","article-title":"Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas","volume":"74","author":"Myerson RJ","year":"2009","unstructured":"Myerson RJ, Garofalo MC, El Naqa I, et al.. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys. 2009, 74:824-30. 10.1016\/j.ijrobp.2008.08.070","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110230","article-title":"Pelvic bone marrow dose-volume predictors of late lymphopenia following pelvic lymph node radiation therapy for prostate cancer","volume":"195","author":"Pavarini M","year":"2024","unstructured":"Pavarini M, Alborghetti L, Aimonetto S, et al.. Pelvic bone marrow dose-volume predictors of late lymphopenia following pelvic lymph node radiation therapy for prostate cancer. Radiother Oncol. 2024, 195:110230. 10.1016\/j.radonc.2024.110230","journal-title":"Radiother Oncol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S195989","article-title":"Correlation between pelvic bone marrow radiation dose and acute hematological toxicity in cervical cancer patients treated with concurrent chemoradiation","volume":"11","author":"Kumar T","year":"2019","unstructured":"Kumar T, Schernberg A, Busato F, et al.. Correlation between pelvic bone marrow radiation dose and acute hematological toxicity in cervical cancer patients treated with concurrent chemoradiation. Cancer Manag Res. 2019, 11:6285-97. 10.2147\/CMAR.S195989","journal-title":"Cancer Manag Res"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-024-03853-7","article-title":"Insights into ionizing radiation-induced bone marrow hematopoietic stem cell injury","volume":"15","author":"Zhang Y","year":"2024","unstructured":"Zhang Y, Chen X, Wang X, Chen J, Du C, Wang J, Liao W. Insights into ionizing radiation-induced bone marrow hematopoietic stem cell injury. Stem Cell Res Ther. 2024, 15:222. 10.1186\/s13287-024-03853-7","journal-title":"Stem Cell Res Ther"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27564","article-title":"Radiation induces iatrogenic immunosuppression by indirectly affecting hematopoiesis in bone marrow","volume":"11","author":"Kapoor V","year":"2020","unstructured":"Kapoor V, Collins A, Griffith K, et al.. Radiation induces iatrogenic immunosuppression by indirectly affecting hematopoiesis in bone marrow. Oncotarget. 2020, 11:1681-90. 10.18632\/oncotarget.27564","journal-title":"Oncotarget"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0904203","article-title":"Hoxa9 regulates Flt3 in lymphohematopoietic progenitors","volume":"185","author":"Gwin K","year":"2010","unstructured":"Gwin K, Frank E, Bossou A, Medina KL. Hoxa9 regulates Flt3 in lymphohematopoietic progenitors. J Immunol. 2010, 185:6572-83. 10.4049\/jimmunol.0904203","journal-title":"J Immunol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1139\/y02-071","article-title":"The effects of ionizing radiation on stem cells and hematopoietic progenitors: the place of apoptosis and the therapeutic potential of anti-apoptosis treatments (Article in French)","volume":"80","author":"Drouet M","year":"2002","unstructured":"Drouet M, Mourcin F, Grenier N, Mayol JF, Leroux V, H\u00e9rodin F, Sotto JJ. The effects of ionizing radiation on stem cells and hematopoietic progenitors: the place of apoptosis and the therapeutic potential of anti-apoptosis treatments (Article in French). Can J Physiol Pharmacol. 2002, 80:700-9. 10.1139\/y02-071","journal-title":"Can J Physiol Pharmacol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.21037\/aob-21-74","article-title":"Lymphocyte response and recovery to radiation therapy alone","volume":"8","author":"Swanson GP","year":"2023","unstructured":"Swanson GP, Hammonds K, Jhavar S. Lymphocyte response and recovery to radiation therapy alone. Ann Blood. 2023, 8:10.21037\/aob-21-74","journal-title":"Ann Blood"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2024.101662","article-title":"The Influence of Pelvic Bone Dose-volume Parameters on Bone Marrow Suppression During Radiation Therapy in Patients With Stage I to III Rectal Cancer Based on Real-world Data","volume":"10","author":"Huang B","year":"2025","unstructured":"Huang B, Lv J, Xiong J, et al.. The Influence of Pelvic Bone Dose-volume Parameters on Bone Marrow Suppression During Radiation Therapy in Patients With Stage I to III Rectal Cancer Based on Real-world Data. Adv Radiat Oncol. 2025, 10:101662. 10.1016\/j.adro.2024.101662","journal-title":"Adv Radiat Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2024.25.11.3799","article-title":"Poor prognostic effects of lymphocytopenia induced by preoperative chemoradiotherapy in rectal cancer","volume":"25","author":"Baik HJ","year":"2024","unstructured":"Baik HJ, An MS, Park JS, Choi Y. Poor prognostic effects of lymphocytopenia induced by preoperative chemoradiotherapy in rectal cancer. Asian Pac J Cancer Prev. 2024, 25:3799-805. 10.31557\/APJCP.2024.25.11.3799","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/mp.16308","article-title":"Radiation hematologic toxicity prediction for locally advanced rectal cancer using dosimetric and radiomics features","volume":"50","author":"Yue H","year":"2023","unstructured":"Yue H, Geng J, Gong L, et al.. Radiation hematologic toxicity prediction for locally advanced rectal cancer using dosimetric and radiomics features. Med Phys. 2023, 50:4993-5001. 10.1002\/mp.16308","journal-title":"Med Phys"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/450962-how-does-lymphocyte-depletion-affect-rectal-cancer-radiotherapy-outcomes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T21:05:11Z","timestamp":1773781511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/450962-how-does-lymphocyte-depletion-affect-rectal-cancer-radiotherapy-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":42,"URL":"https:\/\/doi.org\/10.7759\/cureus.105398","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}